Humana Inc. (HUM) reported $137.20B of revenue for the twelve months ended Mar 31, 2026. That is up 14.1% from the year before. Revenue for fiscal 2025 was $129.66B.

Yes. Humana Inc. earned $1.13B in net income for the twelve months ended Mar 31, 2026, a net margin of 0.8%.

How much cash and debt does HUM have?

Humana Inc. reported $4.95B in cash and cash equivalents and $13.99B of debt on its most recent balance sheet in SEC filings.

How fast is HUM revenue growing?

Humana Inc.'s revenue changed +10.1% in fiscal 2025, to $129.66B. Its compound annual growth rate was +10.9% over 5 years and +9.1% over 10 years.

What is HUM free cash flow?

Humana Inc. generated $1.27B of free cash flow for the twelve months ended Mar 31, 2026, which is operating cash flow of $1.84B less capital expenditures.

What is HUM earnings per share?

Diluted earnings per share were $9.37 for the twelve months ended Mar 31, 2026, from SEC filings, restated for any stock split those filings show.

When did HUM last report financial results?

The latest statements here come from Humana Inc.'s 10-Q filed on Apr 29, 2026, covering the period ended Mar 31, 2026.

Where does this HUM financial data come from?

Quantisnow builds these statements from the structured XBRL data Humana Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · HUM

Humana Inc. (HUM) financials

For the twelve months ended Mar 31, 2026, Humana Inc. reported $137.20B of revenue and $1.13B of net income.

Revenue, TTM: $137.20B
Revenue growth, YoY: +14.1%
Net income, TTM: $1.13B
Net income growth, YoY: -33.9%
Net margin: 0.8%
Free cash flow, TTM: $1.27B
EPS, diluted, TTM: $9.37
EPS growth, YoY: -33.9%
Cash: $4.95B
Total debt: $13.99B
P/E: 46.09
P/S: 0.38
Market cap: $52.08B

Annual revenue$129.66B

FY2016FY2025

Annual net income$1.19B

FY2016FY2025

Annual free cash flow$375.00M

FY2016FY2025

HUM revenue and earnings growth

HUM revenueQ1 2026$39.65B

Quarter YoY: +23.5%
QoQ: +21.9%
FY YoY: +10.1%
5Y CAGR: +10.9%
10Y CAGR: +9.1%

HUM revenue was $39.65B in fiscal Q1 2026 (ended Mar 31, 2026), up 23.5% from a year earlier and up 21.9% from the prior quarter. For the full fiscal 2025 it was $129.66B, up 10.1% from fiscal 2024. Compound annual growth was +10.9% over 5 years and +9.1% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

HUM net incomeQ1 2026$1.19B

Quarter YoY: -4.7%
FY YoY: -1.6%
5Y CAGR: -18.8%
10Y CAGR: -0.7%

HUM net income was $1.19B in fiscal Q1 2026 (ended Mar 31, 2026), down 4.7% from a year earlier. For the full fiscal 2025 it was $1.19B, down 1.6% from fiscal 2024. Compound annual growth was -18.8% over 5 years and -0.7% over 10 years. It rose in 3 of the last 10 fiscal years.

HUM EPSQ1 2026$9.83

Quarter YoY: -4.6%
FY YoY: -1.4%
5Y CAGR: -17.2%
10Y CAGR: +1.5%

HUM diluted EPS was $9.83 in fiscal Q1 2026 (ended Mar 31, 2026), down 4.6% from a year earlier. For the full fiscal 2025 it was $9.84, down 1.4% from fiscal 2024. Compound annual growth was -17.2% over 5 years and +1.5% over 10 years.

HUM free cash flowQ1 2026$1.13B

Quarter YoY: +380.1%
FY YoY: -84.3%
5Y CAGR: -39.6%
10Y CAGR: +0.8%

HUM free cash flow was $1.13B in fiscal Q1 2026 (ended Mar 31, 2026), up 380.1% from a year earlier. For the full fiscal 2025 it was $375.00M, down 84.3% from fiscal 2024. Compound annual growth was -39.6% over 5 years and +0.8% over 10 years. It rose in 5 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$129.66B	$117.76B	$106.37B	$92.87B	$83.06B	$77.16B	$64.89B	$56.91B	$53.77B	$54.38B
Selling, general and admin	$15.45B	$13.70B	$13.19B	$12.67B	$10.12B	$10.05B	$7.38B	$7.53B	$6.57B	$7.17B
Operating income	$2.70B	$2.56B	$4.01B	$3.80B	$3.15B	$4.99B	$3.19B	$3.10B	$4.26B	$1.74B
Interest expense	$631.00M	$660.00M	$493.00M	$401.00M	$326.00M	$283.00M	$242.00M	$218.00M	$242.00M	$189.00M
Pre-tax income	$1.44B	$1.62B	$3.33B	$3.57B	$3.42B	$4.67B	$3.47B	$2.07B	$4.02B	$1.55B
Income tax	$250.00M	$413.00M	$836.00M	$762.00M	$485.00M	$1.31B	$763.00M	$391.00M	$1.57B	$938.00M
Net income	$1.19B	$1.21B	$2.49B	$2.81B	$2.93B	$3.37B	$2.71B	$1.68B	$2.45B	$614.00M
EPS, basic	$9.87	$10.01	$20.09	$22.20	$22.79	$25.47	$20.20	$12.24	$16.94	$4.11
EPS, diluted	$9.84	$9.98	$20.00	$22.08	$22.67	$25.31	$20.10	$12.16	$16.81	$4.07
Diluted shares	120.8M	120.9M	124.4M	127.1M	129.4M	133.0M	134.7M	138.4M	145.6M	150.9M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$4.20B	$2.22B	$4.69B	$5.06B	$3.39B	$4.67B	$4.05B	$2.34B	$4.04B	$3.88B
Short-term investments	$15.70B	$18.21B	$16.63B	$13.88B	$13.19B	$12.55B	$10.97B	-	-	-
Receivables	$3.27B	$2.70B	$2.04B	$1.67B	$1.81B	$1.14B	$1.06B	$1.01B	$854.00M	$1.28B
Current assets	$32.73B	$29.82B	$29.99B	$26.18B	$24.89B	$23.64B	$19.89B	$16.95B	$17.40B	$16.19B
Goodwill	$9.69B	$9.63B	$9.55B	$9.14B	$11.09B	$4.45B	$3.93B	$3.90B	$3.28B	$3.27B
Total assets	$48.91B	$46.48B	$47.06B	$43.05B	$44.36B	$34.97B	$29.07B	$25.41B	$27.18B	$25.40B
Current liabilities	$16.35B	$16.94B	$18.87B	$17.18B	$15.33B	$13.39B	$10.93B	$10.08B	$9.41B	$7.82B
Short-term debt	$0	$577.00M	$1.44B	$2.09B	$1.95B	$600.00M	$699.00M	$1.69B	$150.00M	$300.00M
Long-term debt	$12.37B	$11.14B	$10.21B	$9.03B	$10.54B	$6.06B	$4.97B	$4.38B	$4.77B	$3.79B
Total debt	$12.37B	$11.72B	$11.66B	$11.13B	$12.49B	$6.66B	$5.67B	$6.07B	$4.92B	$4.09B
Total liabilities	$31.17B	$30.03B	$30.75B	$27.68B	$28.25B	$21.24B	$17.04B	$15.25B	$17.34B	$14.71B
Shareholders' equity	$17.66B	$16.45B	$16.32B	$15.37B	$16.10B	$13.73B	$12.04B	$10.16B	$9.84B	$10.69B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$921.00M	$2.97B	$3.98B	$4.59B	$2.26B	$5.64B	$5.28B	$2.17B	$4.05B	$1.94B
Capital expenditures	$546.00M	$575.00M	$1.00B	$1.14B	$1.34B	$964.00M	$736.00M	$612.00M	$524.00M	$527.00M
Free cash flow	$375.00M	$2.39B	$2.98B	$3.45B	$920.00M	$4.67B	$4.55B	$1.56B	$3.53B	$1.41B
Investing cash flow	$2.27B	-$2.95B	-$3.49B	-$1.01B	-$6.56B	-$3.06B	-$1.28B	-$3.09B	-$2.94B	-$1.36B
Financing cash flow	-$1.22B	-$2.49B	-$856.00M	-$1.91B	$3.02B	-$1.96B	-$2.29B	-$785.00M	-$945.00M	$732.00M
Dividends paid	$430.00M	$431.00M	$431.00M	$392.00M	$354.00M	$323.00M	$291.00M	$265.00M	$220.00M	$177.00M
Share repurchases	$151.00M	$817.00M	$1.57B	$2.10B	$79.00M	$1.82B	$1.07B	$1.09B	$3.37B	$104.00M
Stock-based compensation	$241.00M	$207.00M	$175.00M	$216.00M	$180.00M	$181.00M	$163.00M	$137.00M	$157.00M	$115.00M
Depreciation and amortization	$698.00M	$839.00M	$779.00M	$709.00M	$596.00M	-	-	$444.00M	$410.00M	$388.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	10.1%	10.7%	14.5%	11.8%	7.7%	18.9%	14.0%	5.8%	-1.1%	0.2%
Net income growth, YoY	-1.6%	-51.5%	-11.3%	-4.3%	-12.9%	24.4%	60.8%	-31.3%	298.7%	-51.9%
EPS growth, YoY	-1.4%	-50.1%	-9.4%	-2.6%	-10.4%	25.9%	65.3%	-27.7%	313.0%	-51.8%
Operating margin	2.1%	2.2%	3.8%	4.1%	3.8%	6.5%	4.9%	5.4%	7.9%	3.2%
Net margin	0.9%	1.0%	2.3%	3.0%	3.5%	4.4%	4.2%	3.0%	4.6%	1.1%
Free cash flow margin	0.3%	2.0%	2.8%	3.7%	1.1%	6.1%	7.0%	2.7%	6.6%	2.6%
Return on equity	6.7%	7.3%	15.3%	18.3%	18.2%	24.5%	22.5%	16.6%	24.9%	5.7%
Return on assets	2.4%	2.6%	5.3%	6.5%	6.6%	9.6%	9.3%	6.6%	9.0%	2.4%
Current ratio	2.00	1.76	1.59	1.52	1.62	1.77	1.82	1.68	1.85	2.07
Debt to equity	0.70	0.71	0.71	0.72	0.78	0.49	0.47	0.60	0.50	0.38

Income statement

Income statement
Line item	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023	Q3 2023 Sep 30, 2023	Q2 2023 Jun 30, 2023
Revenue	$39.65B	$32.52B	$32.65B	$32.39B	$32.11B	$29.21B	$29.40B	$29.54B	$29.61B	$26.46B	$26.42B	$26.75B
Selling, general and admin	$4.02B	$4.44B	$4.08B	$3.55B	$3.38B	$4.17B	$3.34B	$3.15B	$3.04B	$3.83B	$3.27B	$3.11B
Operating income	$1.75B	-$808.00M	$400.00M	$1.10B	$2.01B	-$543.00M	$728.00M	$1.14B	$1.24B	-$348.00M	$1.21B	$1.44B
Interest expense	$193.00M	$146.00M	$168.00M	$157.00M	$160.00M	$164.00M	$169.00M	$168.00M	$159.00M	$146.00M	$114.00M	$120.00M
Pre-tax income	$1.59B	-$1.13B	$134.00M	$741.00M	$1.69B	-$963.00M	$651.00M	$918.00M	$1.01B	-$610.00M	$1.09B	$1.25B
Income tax	$395.00M	-$249.00M	-$86.00M	$179.00M	$406.00M	-$216.00M	$155.00M	$223.00M	$251.00M	-$75.00M	$256.00M	$296.00M
Net income	$1.19B	-$796.00M	$195.00M	$545.00M	$1.24B	-$693.00M	$480.00M	$679.00M	$741.00M	-$541.00M	$832.00M	$959.00M
EPS, basic	$9.85	-$6.58	$1.62	$4.52	$10.31	-$5.74	$3.99	$5.63	$6.13	-$4.26	$6.74	$7.70
EPS, diluted	$9.83	-$6.59	$1.62	$4.51	$10.30	-$5.73	$3.98	$5.62	$6.11	-$4.24	$6.71	$7.66
Diluted shares	120.7M	-	120.7M	120.7M	120.8M	-	120.8M	120.7M	121.3M	-	124.0M	125.1M

Balance sheet

Balance sheet
Line item	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023	Q3 2023 Sep 30, 2023	Q2 2023 Jun 30, 2023
Cash and equivalents	$4.95B	$4.20B	$5.39B	$4.04B	$4.25B	$2.22B	$5.12B	$5.50B	$5.91B	$4.69B	$15.15B	$16.21B
Short-term investments	$17.01B	$15.70B	$16.74B	$17.67B	$17.89B	$18.21B	$19.03B	$17.42B	$16.70B	$16.63B	$15.14B	$15.25B
Receivables	$5.22B	$3.27B	$2.68B	$4.50B	$4.46B	$2.70B	$2.14B	$4.09B	$3.92B	$2.04B	$1.82B	$1.43B
Current assets	$38.08B	$32.73B	$32.75B	$33.62B	$34.42B	$29.82B	$32.93B	$32.86B	$32.80B	$29.99B	$38.25B	$38.76B
Goodwill	$10.49B	$9.69B	$9.62B	$9.63B	$9.63B	$9.63B	$9.59B	$9.57B	$9.56B	$9.55B	$9.54B	$9.54B
Total assets	$55.28B	$48.91B	$49.72B	$50.36B	$50.93B	$46.48B	$50.01B	$50.09B	$50.09B	$47.06B	$55.91B	$56.45B
Current liabilities	$21.51B	$16.35B	$16.18B	$17.22B	$18.04B	$16.94B	$18.73B	$19.79B	$19.69B	$18.87B	$27.82B	$28.28B
Short-term debt	$1.72B	$0	$0	$0	$577.00M	$577.00M	$1.14B	$1.15B	$822.00M	$1.44B	$2.25B	$2.02B
Long-term debt	$12.27B	$12.37B	$12.61B	$12.59B	$12.73B	$11.14B	$11.89B	$11.75B	$12.39B	$10.21B	$9.48B	$9.72B
Total debt	$13.99B	$12.37B	$12.61B	$12.59B	$13.31B	$11.72B	$13.02B	$12.89B	$13.21B	$11.66B	$11.73B	$11.74B
Total liabilities	$36.63B	$31.17B	$31.14B	$32.06B	$33.11B	$30.03B	$32.38B	$33.37B	$33.91B	$30.75B	$38.90B	$39.56B
Shareholders' equity	$18.58B	$17.66B	$18.52B	$18.30B	$17.82B	$16.45B	$17.62B	$16.73B	$16.19B	$16.32B	$17.00B	$16.89B

Cash flow

Cash flow
Line item	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023	Q3 2023 Sep 30, 2023	Q2 2023 Jun 30, 2023
Operating cash flow	$1.25B	-$1.65B	$971.00M	$1.27B	$331.00M	-$528.00M	$1.86B	$1.21B	$423.00M	-$7.13B	$1.25B	$3.18B
Capital expenditures	$121.00M	$202.00M	$135.00M	$114.00M	$95.00M	$154.00M	$130.00M	$114.00M	$177.00M	$283.00M	$234.00M	$264.00M
Free cash flow	$1.13B	-$1.85B	$836.00M	$1.16B	$236.00M	-$682.00M	$1.73B	$1.10B	$246.00M	-$7.42B	$1.02B	$2.91B
Investing cash flow	-$2.55B	$632.00M	$980.00M	$347.00M	$314.00M	-$63.00M	-$1.47B	-$1.00B	-$414.00M	-$882.00M	-$585.00M	-$733.00M
Financing cash flow	$2.05B	-$168.00M	-$603.00M	-$1.83B	$1.38B	-$2.30B	-$770.00M	-$620.00M	$1.21B	-$2.44B	-$1.73B	$36.00M
Dividends paid	$107.00M	$109.00M	$107.00M	$106.00M	$108.00M	$108.00M	$107.00M	$107.00M	$109.00M	$111.00M	$109.00M	$111.00M
Share repurchases	$107.00M	$42.00M	$0	$100.00M	$9.00M	$49.00M	$2.00M	$49.00M	$717.00M	$571.00M	$379.00M	$529.00M
Stock-based compensation	$51.00M	$48.00M	$83.00M	$61.00M	$49.00M	$54.00M	$53.00M	$55.00M	$45.00M	$33.00M	$53.00M	$51.00M
Depreciation and amortization	$163.00M	$164.00M	$173.00M	$178.00M	$183.00M	$208.00M	$210.00M	$212.00M	$209.00M	$201.00M	$201.00M	$191.00M

Key ratios

Key ratios
Line item	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023	Q3 2023 Sep 30, 2023	Q2 2023 Jun 30, 2023
Revenue growth, YoY	23.5%	11.3%	11.1%	9.6%	8.4%	10.4%	11.3%	10.4%	10.7%	17.9%	15.9%	13.0%
Net income growth, YoY	-4.7%	-	-59.4%	-19.7%	67.9%	-	-42.3%	-29.2%	-40.2%	-	-30.4%	37.8%
EPS growth, YoY	-4.6%	-	-59.3%	-19.8%	68.6%	-	-40.7%	-26.6%	-38.1%	-	-28.5%	39.8%
Operating margin	4.4%	-2.5%	1.2%	3.4%	6.3%	-1.9%	2.5%	3.9%	4.2%	-1.3%	4.6%	5.4%
Net margin	3.0%	-2.4%	0.6%	1.7%	3.9%	-2.4%	1.6%	2.3%	2.5%	-2.0%	3.1%	3.6%
Free cash flow margin	2.9%	-5.7%	2.6%	3.6%	0.7%	-2.3%	5.9%	3.7%	0.8%	-28.0%	3.9%	10.9%
Current ratio	1.77	2.00	2.02	1.95	1.91	1.76	1.76	1.66	1.67	1.59	1.37	1.37
Debt to equity	0.75	0.70	0.68	0.69	0.75	0.71	0.74	0.77	0.82	0.71	0.69	0.70

Source: XBRL data Humana Inc. files with the SEC, latest filing dated Apr 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

HUM peers

Company	Revenue	Growth	Net income	Net margin	Market cap
HUM	$137.20B	+14.1%	$1.13B	0.8%	$52.08B
UNHUnitedHealth Group Incorporated	$449.66B	+3.3%	$15.88B	3.5%	$353.17B
ELVElevance Health Inc.	$201.83B	+3.6%	$5.13B	2.5%	$91.96B
CIThe Cigna Group	$286.32B	+6.8%	$5.99B	2.1%	$77.58B
NTRANatera Inc.	$2.91B	+37.4%	-$164.71M	-5.7%	$44.78B
CNCCentene Corporation	$203.90B	+9.7%	$1.46B	0.7%	$34.53B
ILMNIllumina Inc.	$4.54B	+5.8%	$895.00M	19.7%	$32.22B
LHLabcorp Holdings Inc.	$14.59B	+6.0%	$1.00B	6.9%	$29.77B
DGXQuest Diagnostics Incorporated	$11.84B	+9.1%	$1.13B	9.5%	$28.12B

HUM FAQ

8 questions

What is HUM revenue?
Humana Inc. (HUM) reported $137.20B of revenue for the twelve months ended Mar 31, 2026. That is up 14.1% from the year before. Revenue for fiscal 2025 was $129.66B.
Is HUM profitable?
Yes. Humana Inc. earned $1.13B in net income for the twelve months ended Mar 31, 2026, a net margin of 0.8%.
How much cash and debt does HUM have?
Humana Inc. reported $4.95B in cash and cash equivalents and $13.99B of debt on its most recent balance sheet in SEC filings.
How fast is HUM revenue growing?
Humana Inc.'s revenue changed +10.1% in fiscal 2025, to $129.66B. Its compound annual growth rate was +10.9% over 5 years and +9.1% over 10 years.
What is HUM free cash flow?
Humana Inc. generated $1.27B of free cash flow for the twelve months ended Mar 31, 2026, which is operating cash flow of $1.84B less capital expenditures.
What is HUM earnings per share?
Diluted earnings per share were $9.37 for the twelve months ended Mar 31, 2026, from SEC filings, restated for any stock split those filings show.
When did HUM last report financial results?
The latest statements here come from Humana Inc.'s 10-Q filed on Apr 29, 2026, covering the period ended Mar 31, 2026.
Where does this HUM financial data come from?
Quantisnow builds these statements from the structured XBRL data Humana Inc. files with the SEC. It is provided for information only and is not investment advice.